Business
Appointment of Chief Financial Officer
Appointment of Chief Financial Officer.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n\n\nAllergy Therapeutics plc\n(\"Allergy Therapeutics\", the \"Group\" or \"Company\")\n \nAppointment of Chief Financial Officer\n \n10 July 2023 Allergy Therapeutics plc (AIM: AGY), the integrated commercial biotechnology company specialising in allergy vaccines, is pleased to announce the promotion of Shaun Furlong to Chief Financial Officer (CFO) with effect from 11 August, when the current interim CFO, Martin Hopcroft, will leave the Company.\n \nShaun brings significant financial experience in both technical and commercial roles. He joined Allergy Therapeutics as Group Financial Controller and a member of the Group's senior management team in April 2022. He previously held senior finance roles within blue-chip companies across multiple sectors, including Legal & General, Hastings Direct, Volution Group and American Express. He is a Fellow of the Institute of Chartered Accountants in England and Wales, and holds a PhD in polymer chemistry from the University of Sussex.\n \nManuel Llobet, Chief Executive Officer, said: \"I have had the pleasure of working with Shaun for some time in his role as Group Financial Controller for the Company and know him to be highly diligent and professional with strong business acumen, so am delighted to welcome him in his new role. I also want to take this opportunity to thank Martin Hopcroft for his expertise and commitment during his time as interim CFO over recent months and wish him the best for the future.\"\n \nShaun Furlong, incoming Chief Financial Officer, said: \"I am excited to step into my new role as CFO of Allergy Therapeutics, a pioneering company shaping the future of innovative immunotherapies. Leveraging my industry experience, I look forward to working with the leadership team.\"\n \n \nFor further information, please contact:\n \nAllergy Therapeutics\nManuel Llobet, Chief Executive Officer\nMartin Hopcroft, Interim Chief Financial Officer\n+44 (0)1903 845 820\n \nPanmure Gordon (Nominated Adviser and Broker)\nFreddy Crossley, Emma Earl, Corporate Finance\nRupert Dearden, Corporate Broking\n+44 (0)20 7886 2500\n \nConsilium Strategic Communications\nMary-Jane Elliott / David Daley / Davide Salvi\n+44 (0)20 3709 5700\[email protected]\n \n \nNotes for editors:\n \nAbout Allergy ...